









Markets
/
Stocks
/
nasdaq-sls
/

Sellas Life Sciences Group Inc

SLS

3.730USD

+0.200+5.67%

Close 02/06, 16:00（ET）Quotes delayed by 15 min

466.54MMarket Cap

LossP/E TTM



Sellas Life Sciences Group Inc

3.730

+0.200+5.67%

Overview Financials Analysis Company

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

Overview

Financials

Analysis

Company

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

TradingKey Stock Score of Sellas Life Sciences Group Inc

Currency: USD Updated: 2026-02-06

Key Insights

Sellas Life Sciences Group Inc's fundamentals are relatively very healthy, with an industry-leading ESG disclosure.and its growth potential is high.Its valuation is considered fairly valued, ranking 113 out of 392 in the Biotechnology & Medical Research industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 6.83.In the medium term, the stock price is expected to trend up.The company has been performing well in the stock market over the past month, which is supported by its strong fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Sellas Life Sciences Group Inc's Score

Industry at a Glance

Industry Ranking

113 / 392

Overall Ranking

246 / 4521

Industry

Biotechnology & Medical Research

Support & Resistance

Relevant data have not been disclosed by the company yet.

Score Analysis

Current score

Previous score

Media Coverage

Last 24 hours

Coverage Level

Very Low

Very High

Neutral

Sellas Life Sciences Group Inc Highlights

StrengthsRisks

SELLAS Life Sciences Group, Inc. is a late-stage clinical biopharmaceutical company. The Company is focused on the development of therapeutics for a range of cancer indications. The Company's product candidates are galinpepimut-S (GPS), a peptide immunotherapy directed against the Wilms tumor 1 (WT1), antigen, and SLS009, a selective small molecule cyclin-dependent kinase 9 (CDK9) inhibitor. GPS is a cancer immunotherapeutic agent licensed by Memorial Sloan Kettering Cancer Center (MSK), that targets the WT1 protein, which is present in an array of tumor types. GPS has potential as a monotherapy or in combination with other immunotherapeutic agents to address a broad spectrum of hematologic malignancies and solid tumor indications. The Company is developing SLS009, which is licensed by GenFleet Therapeutics (Shanghai), Inc., for all therapeutic and diagnostic uses in the world outside of mainland China, Hong Kong, Macau, and Taiwan.

Undervalued

The company’s latest PE is -13.52, at a low 3-year percentile range.

Institutional Buying

The latest institutional holdings are 35.56M shares, increasing 11.52% quarter-over-quarter.

Held by The Vanguard

Star Investor The Vanguard holds 8.47M shares of this stock.

Lower Market Activity

The company has less investor interest, with a 20-day turnover ratio of -0.25.

Analyst Rating

Based on 3 analysts

Buy

Current Rating

6.833

Target Price

+93.58%

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Financial Health

Currency: USD Updated: 2026-02-06

The current financial score of Sellas Life Sciences Group Inc is 6.98, ranking 173 out of 392 in the Biotechnology & Medical Research industry. Its financial status is robust, and its operating efficiency is low.

Score

Industry at a Glance

Previous score

6.98

Change



Financials

10.00

Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

Relevant data have not been disclosed by the company yet.



Quality of Earnings

8.36

Key Metrics

Total revenue

Operating profit

Total assets

SG&A

Relevant data have not been disclosed by the company yet.



Operational Efficiency

2.77

Key Metrics

Cash flow from operating activities

Income after tax

Relevant data have not been disclosed by the company yet.



Growth Potential

6.75

Key Metrics

Cash flow from operating activities

Total revenue

Relevant data have not been disclosed by the company yet.



Shareholder Returns

7.03

Key Metrics

Free cash flow

Relevant data have not been disclosed by the company yet.

Sellas Life Sciences Group Inc's Company Valuation

Currency: USD Updated: 2026-02-06

The current valuation score of Sellas Life Sciences Group Inc is 6.08, ranking 333 out of 392 in the Biotechnology & Medical Research industry. Its current P/E ratio is -13.52, which is -97.22% below the recent high of -0.38 and -34.05% above the recent low of -18.12.

Score

Industry at a Glance

Previous score

6.08

Change

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 113/392

Relevant data have not been disclosed by the company yet.

Earnings Forecast

Currency: USD Updated: 2026-02-06

The current earnings forecast score of Sellas Life Sciences Group Inc is 8.67, ranking 70 out of 392 in the Biotechnology & Medical Research industry. The average price target is 7.00, with a high of 7.50 and a low of 6.00.

Score

Industry at a Glance

Previous score

8.67

Change

Support & Resistance

Relevant data have not been disclosed by the company yet.

Analyst Rating

Based on 3 analysts

Buy

Current Rating

6.833

Target Price

+93.58%

Upside Space

Strong Buy

Buy

Hold

Sell

Strong Sell

Peer Comparison

542

Total

Median

Average

Company name

Ratings

Analysts

Sellas Life Sciences Group Inc

SLS

CRISPR Therapeutics AG

CRSP

argenx SE

ARGX

IQVIA Holdings Inc

IQV

Beigene Ltd

ONC

Intellia Therapeutics Inc

NTLA

...

109

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

Relevant data have not been disclosed by the company yet.

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Price Momentum

Currency: USD Updated: 2026-02-06

The current price momentum score of Sellas Life Sciences Group Inc is 7.22, ranking 88 out of 392 in the Biotechnology & Medical Research industry. Currently, the stock price is trading between the resistance level at 4.64 and the support level at 3.03, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score

7.01

Change

0.21

Support & Resistance

Relevant data have not been disclosed by the company yet.

Indicators



The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

Indicators

Sell(2)

Neutral(2)

Buy(1)

Indicators

Value

Direction

MACD(12,26,9)

-0.264

Neutral

RSI(14)

49.429

Neutral

STOCH(KDJ)(9,3,3)

17.336

Oversold

ATR(14)

0.412

Low Volatility

CCI(14)

-106.183

Sell

Williams %R

81.919

Oversold

TRIX(12,20)

0.648

Sell

StochRSI(14)

31.547

Buy

Moving Average

Sell(3)

Neutral(0)

Buy(3)

Indicators

Value

Direction

MA5

3.842

Sell

MA10

3.954

Sell

MA20

4.043

Sell

MA50

3.139

Buy

MA100

2.447

Buy

MA200

2.092

Buy

Institutional Confidence

Currency: USD Updated: 2026-02-06

The current institutional shareholding score of Sellas Life Sciences Group Inc is 3.00, ranking 197 out of 392 in the Biotechnology & Medical Research industry. The latest institutional shareholding proportion is 20.88%, representing a quarter-over-quarter decrease of 21.08%. The largest institutional shareholder is The Vanguard, holding a total of 8.47M shares, representing 4.97% of shares outstanding, with 59.19% increase in holdings.

Score

Industry at a Glance

Previous score

3.00

Change

Institutional Shareholding

Relevant data have not been disclosed by the company yet.

Shareholder Activity

Name

Shares Held

Chg %

The Vanguard Group, Inc.

Star Investors

6.84M

+2.78%

Anson Funds Management LP.

6.03M

+2093.80%

BlackRock Institutional Trust Company, N.A.

5.19M

+24.54%

Marshall Wace LLP

2.36M

-13.16%

Geode Capital Management, L.L.C.

2.26M

+2.91%

State Street Investment Management (US)

1.36M

+22.31%

Nuveen LLC

971.33K

Susquehanna International Group, LLP

863.58K

-42.03%

Northern Trust Investments, Inc.

700.61K

+2.56%

Risk Assessment

Currency: USD Updated: 2026-02-06

The U.S. Dollar Index is currently in a neutral state, which has a neutral effect on the Biotechnology & Medical Research domestic-focused industry. The Dollar Index (DXY) measures the value of the U.S. dollar against a basket of major currencies, including the euro, yen, pound sterling, Canadian dollar, Swedish krona, and Swiss franc. The current risk assessment score of Sellas Life Sciences Group Inc is 3.21, ranking 164 out of 392 in the Biotechnology & Medical Research industry. The company's beta value is 2.25. This indicates that the stock tends to outperform the index during upward trending markets but experiences larger declines during downward trending markets. with an industry-leading ESG disclosure.